Evidence-based Reconstruction of Kampo Medicine: Part-III—How Should Kampo be Evaluated? by Terasawa, Katsutoshi
Introduction
In the previous two lectures, I tried to explain in detail that the
paradigm of Kampo is basically different from that of modern
Western medicine, focusing especially on the concept of Sho.
Kampo has been developed to cope with Sho, not with the dis-
ease entities understood in terms of modern Western medicine.
Thus, there is little point asking, for example, ‘Are there any
Kampo remedies effective for lung cancer (or type C hepatitis,
or essential hypertension)?’
This question, asked wrongly, however, highlights two
important issues, one intriguing and long term, and the other
important and short term. The former is that the effects of
Kampo herbs have so far not been tested properly against any
of the specific disease entities defined in the framework of
modern Western medicine. The latter is that we urgently need
some methods to accommodate evaluation of the clinical
effects of Kampo remedies in the framework of evidence-
based medicine of the West.
Kampo as a Frontier of Research on
Complex Agents (drugs): a Long-term View
It may sound paradoxical that the effects of various Kampo
regimens so far have not been tested properly against any spe-
cific disease entities, given that these remedies have been in
use for thousands of years for patients with a wide variety of
disorders in East Asia. However, if we remember that the
modern Western framework of diseases is only a couple of
hundreds years old and people (patients and doctors alike) who
used Kampo herbs had never been acquainted with any con-
cepts such as lung cancer, type C hepatitis or angina pectoris,
the issue raised here should become understandable. It has
sometimes been claimed that the fact that Kampo medicine is
effective is beyond doubt as it has endured thousands of years
of ‘clinical testing’by East Asian people. However, this is only
so for Sho, or symptom conditions understood in the frame-
work of Kampo. In other words, Kampo has been proven
effective for Sho conditions, but not for any others. The effects
of Kampo medicine on disease entities understood in the
framework of modern Western medicine should be the subject
of novel research. For example, in the first issue of eCAM,
Kobayashi et al. (1) described in detail their clinical experi-
ence on the application of Kampo remedies for atopic
dermatitis. As the very concept of atopic dermatitis is only half
a century old, research on the effects of any Kampo agents on
atopic dermatitis is basically brand new or, in other words,
purely experimental. In that review, the authors reported their
struggle to bring atopic dermatitis under control by various
Kampo formulae. According to the authors, very few patients
with atopic dermatitis refractory to modern Western remedies
can be cured by one single formula of Kampo, but usually
several formulae should be tried out against changing
Sho, until the patients’ symptoms are brought under control.
Therefore, they say, it would be better to call their Kampo ther-
apy a Kampo ‘session’, not a simple ‘administration’ of a
single (or multiple) synthetic drug(s). This is a paradigmatic
case to show that there are very few one-to-one correspon-
dences between disease entities in modern Western terms and
Kampo remedies. Kampo is not effective for atopic dermatitis
in the way, for instance, that streptomycin is effective for
tuberculosis. This situation has two intriguing implications.
First, trying to find applications of Kampo medicine for
‘modern Western’ diseases itself is a venture into a new field.
For example, it is a completely new quest to look for some
Kampo remedies which are effective for, say, AIDS, type
C hepatitis or prostate cancer. Secondly, in looking for appli-
cations of Kampo medicine to modern Western disease
entities, it is not mandatory for a researcher to stay within the
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derivative work this must be clearly indicated.framework of the traditional Kampo formulation. This may
sound paradoxical, since of course some of the traditional for-
mulae could be found to be effective for some disease entities,
as indeed they have already been. However, there are other
intriguing possibilities such as: (i) one particular chemical
component in a Kampo herb may ultimately be found to be
effective; (ii) one special composition of several chemical
components in one kind of Kampo herb may be found to be
effective; or (iii) a new combination of several traditional
Kampo herbs may be found to be effective for some disease
entities defined in the modern Western framework. In method-
ological terms, there are several procedures to pursue these
possibilities. First, the effects of Kampo remedies can be tried
out for as many disease entities as possible in pre-clinical set-
tings, especially for diseases for which there is no effective
synthetic chemical drug. Secondly, in doing that, researchers
do not have to take the traditional formulae as invincible, as
they have not been nurtured as agents for, for example, AIDS.
A very ‘reductionist’ approach can even be taken to look for
‘active component(s)’ in the complex herbal formulae. Such
approaches have already been being tried in various laborato-
ries in Japan.
Kampo agents have not only not been tested properly for
their effects against any modern disease entities, but they had
also not been evaluated for their effects on any physiological,
biochemical or immunological functions up until the middle of
the last century. Thus, research such as the effects of
Juzentaihoto on cytokine production published in the first
issue of eCAM (2) is among the first to be tried in the thou-
sands of years of history of Traditional Chinese Medicine and
Kampo. Basic chemical analyses of almost all the Kampo
herbs had been nearly completed by ~1980 in many laborato-
ries especially in Japan, and research has flourished in looking
at the effects of Kampo herbs on a variety of physiological,
pharmacological, immunological and other parameters at the
laboratory level. However, research into actions of many of
Kampo component herbs and also various Kampo formulae is
far from complete. As has been stressed in this lecture series
(3,4) and also in several other articles in eCAM (5), the ‘com-
posite’ effects of Kampo herbs are the most important and
interesting field of research for the future.
From one perspective, we can even see that the thousands of
years of experience in East Asia have generated a vast volume
of ‘clinical suggestions’ or ‘epidemiological raw data’ that
some herbs or combination of herbs are effective on some dis-
eases or some physiological processes. To determine what
herbal component(s)/herbs/combination herbs are effective for
what kind of diseases or what pathophysiological processes is
essentially a new field of basic research. Given the complexity
of Kampo herbs and their composite preparations, this is a
long-term project, not much different from conventional clini-
copharmaceutical research to determine effective antibacterial
products from fungi and other organisms. The major difference
between Kampo research and such a conventional approach is
its attention to composite effects. Methodologies being devel-
oped for that aspect of Kampo will help conventional drug
research to become more attentive to the possibility of such
effects.
As a final note for this section, I would like to point out one
more interesting aspect for long-term research on Kampo.
Kampo agents, being herbal preparations, cannot only be
regarded as ‘drugs’, but can also be seen as special ‘foods’, as
exemplified by the famous Kampo slogan, ‘Foods and drugs,
from the same origin’. If so, ‘effects’of Kampo agents can not
only be evaluated from the viewpoint of drugs to ‘cure’ spe-
cific diseases, as for paradigmatic modern Western synthetic
drugs. They can also be evaluated for their efficacy to ‘prevent’
a variety of pathological conditions, especially lifestyle-related
diseases including cancer and ‘metabolic syndrome’. If we
rememeber that Chinese tea was actually a ‘drug’ in ancient
East Asia which has now become a subject of serious study for
the chemoprevention of cancer (6), this viewpoint will be well
justified. I hope imaginative epidemiological studies in the
East will track down interesting candidates for further analyti-
cal research among Kampo agents.
Evaluation of Kampo Formulae on Disease
Entities in the Modern Western Framework:
Standard and Novel Clinical Trials
Standard Double-blind Randomized Control Trials
(RCTs)
The issues raised above are long-term and basic issues.
However, Kampo medicine is now facing a more urgent and
short-term challenge today. Society and governmental regula-
tors are pressing for evidence to be presented regarding its
efficacy. Simply put, there is clear demand that Kampo medi-
cine should be evaluated on the same grounds and by the same
methodology as synthetic drugs against disease entities in the
modern Western framework. Many Kampo practitioners and
researchers have been reluctant to comply with such demands,
for the reasons repeated many times, namely paradigm differ-
ences related to the Sho concept. However, in the last decade,
especially in Japan, there have been several attempts to evalu-
ate Kampo agents in order to meet such demands. I would like
to point out here that such a standard clinical trial is only
possible if the drugs evaluated are highly homogeneous, and
thus for Kampo herbs such quality control has only been
possible for products from Japan.
As far as I am aware, there have been six reliable reports of
standard double-blind randomized control trials on Kampo
formulae after 1990, though unfortunately only one of them is
completely in English (7). The report was from my own labo-
ratory, examining the effect of Choto-san on vascular demen-
tia. The result simply showed that Choto-san was more
effective than placebo in ‘general improvement’ and ‘useful-
ness’ against vascular dementia. Other studies reported in
Japanese with abstracts in English available are: Daiokanzoto
on constipation (8), Shoseiryuto on nasal allergy (9) and
Shakuyakukanzoto on muscular cramp (10). In all of these
studies, Kampo agents were superior to placebo in a wide
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at all, but it should be noted that there is no element of the
authentic Kampo approach, namely that based on Sho,
involved in these ‘standard’ trials. Kampo agents were just
treated as ‘drugs’ in the modern Western framework. Many
Kampo practitioners thought this approach was unfair.
A Modified Double-blind RCT Based on Sho
There was one report in 1998 by Harasawa and his collabora-
tors, though again only in Japanese with no abstract in English,
in which an RCT was attempted on a Kampo agent by taking
Sho into account. Its study design was simple. The overall
objective was to see if Rikkunshito is effective against dys-
motility-like dyspepsia. In enrolling 235 subjects into the trial,
the authors introduced inclusion and exclusion criteria where
they included those who showed Sho indicative of Rikkunshito
(which is Kyo-Sho) for the formula, but excluded those who
showed Sho not indicative for Rikkunshito (such as muscular
physique or ruddy face). As the formula has a peculiarly bitter
‘Kampo’taste, the investigators mixed into the placebo a lower
(10%) dose of Rikkunshito. The results showed that the
formula was significantly (P   0.001) more ‘effective’
(59.3%) than placebo (40.2%) in improving the dysmotility-
like dyspepsia and also was more ‘useful’(58.8 versus 39.3%,
P   0.003). Interestingly, after stratified analysis, it was found
that the formula was more effective (P   0.001) when patients
exhibited clearer Kyo-Sho (e.g. lowered muscular tonus in the
abdomen) at the initial examination.
This type of trial (‘pre-stratification according to Sho’) is
quite interesting and may look promising especially for
researchers in the West. However, this type of trial design has
again met with criticism from Kampo practitioners. This is
basically because this design presupposes that Sho would not
change during the trial, which is inconceivable in the Kampo
paradigm. As explained in detail in the previous lecture, it is a
rule and not an exception that Sho, being a concept of ‘phe-
nomenon’, would change day by day, or even hour by hour.
Such ‘fluidity’ in Sho makes a trial design such as that above
difficult actually to carry out. The difficulty of incorporating
Sho into rigid inclusion/exclusion criteria (such as age and
sex) will be well understood if one could imagine that such
phenomena or symptoms as ‘fatigue’ or ‘malaise’ are to be
taken as inclusion/exclusion criteria in a formal RCT.
New Trial Designs Being Investigated
We have been trying to devise trial designs for Kampo, in
which the main features of the Kampo approach are taken into
considerations. I would like to outline one such design here
(Fig. 1). In this scheme, first the Kampo agent being tested is
tried for those whom the practitioners find to have its Sho (run-
in period). After 2 weeks, those who do not respond to the agent
are excluded from the trial. In this way, only those who exhibit
appropriate Sho are selected from the patients with the disease
category for which the agent is tried. We call this process
‘responder restriction’ according to Sho. After this run-in
period, patients are randomized into three groups: two groups
with the real Kampo agent and one group with the placebo.
After 6 weeks of the trial, the patients are assessed, and a
2 week wash-out period is introduced; subsequently, for the
same three groups of patients, those who took placebo are
changed to taking the real agent, while for one of the other two
groups the real agent is changed for placebo. This is a sort of
‘cross-over trial’, where not only the effect of the Kampo agent
is tested against placebo but in some of the participants the
effect of the former is directly compared with the latter in indi-
vidual patients. Thus, this scheme is regarded to be introducing
the element of an ‘N of one’trial method as proposed by Guyatt
et al. (11). We think such a scheme would make sense in the
Kampo setting, where response varies widely among individual
patients and thus the effect of one kind of agent should be
assessed against placebo in one individual patient.
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